Top news of the week: 04.03.2021.
Companies And Industries
FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine
The FDA issued an EUA for the Janssen COVID-19 Vaccine, allowing the vaccine to be distributed in the U.S for use in individuals 18 years of age and older.
Scientists Sequence 64 Human Genomes as New Reference for Genetic Diversity
New dataset could ultimately be used to to help develop more targeted, personalized treatments and preventative medicine.
Gossamer Bio seeking out partners for failed DP2 antagonist, says it has 'viable path forward'
Gossamer Bio has been unraveling over the past year, hit hard by a failure for its leading drug program and the axing of its CEO Sheila Gujrathi soon after.
2021 Biopharma Update on the Novel Coronavirus: March 2
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 2, 2021.
Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma
TARRYTOWN, N.Y. , Feb. 27, 2021 /PRNewswire/ -- Single administration of novel antibody cocktail controlled patients' allergic response to cat allergen, preventing early asthma reactions ...
A third COVID-19 vaccine
It’s March, again—but things are looking up because the FDA authorized a third COVID-19 vaccine for emergency use. We have details, plus USDA’s proposed framework for regulatory oversight ...
A new kind of biotech upstart inspired by a top MIT finance professor just received a crucial validation, and rivals are now copying its strategy. BridgeBio's CEO says it's just getting started.
BridgeBio just received FDA approval for its first drug for an ultra-rare disease. It's the first proof-point for a company that drew skepticism.
NJBIZ Conversations: Will Lewis
The CEO of Bridgewater-based Insmed discusses the company's products -- which target rare and serious diseases, including COVID-19, his outlook for the next several months and the role ...